{"id": "article-88698_0", "title": "Fludrocortisone -- Continuing Education Activity", "content": "This activity\u00a0discusses\u00a0the synthetic adrenal steroid fludrocortisone, which possesses potent mineralocorticoid activity. Normally prescribed for adrenocortical insufficiency, its versatile off-label applications extend to managing orthostatic hypotension and postural orthostatic tachycardia syndrome. By exploring its mechanism of action, adverse event profile, and other critical aspects, including\u00a0dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions,\u00a0participants gain essential insights to administer fludrocortisone\u00a0for various indications adeptly. Understanding fludrocortisone's pharmacology empowers healthcare professionals to make informed therapeutic decisions and optimize patient care outcomes, particularly in adrenocortical insufficiency treatment. Equipping healthcare professionals with this practical guide enhances their capacity to navigate complex medical scenarios, elevating the standard of healthcare delivery and ultimately improving patient outcomes.", "contents": "Fludrocortisone -- Continuing Education Activity. This activity\u00a0discusses\u00a0the synthetic adrenal steroid fludrocortisone, which possesses potent mineralocorticoid activity. Normally prescribed for adrenocortical insufficiency, its versatile off-label applications extend to managing orthostatic hypotension and postural orthostatic tachycardia syndrome. By exploring its mechanism of action, adverse event profile, and other critical aspects, including\u00a0dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions,\u00a0participants gain essential insights to administer fludrocortisone\u00a0for various indications adeptly. Understanding fludrocortisone's pharmacology empowers healthcare professionals to make informed therapeutic decisions and optimize patient care outcomes, particularly in adrenocortical insufficiency treatment. Equipping healthcare professionals with this practical guide enhances their capacity to navigate complex medical scenarios, elevating the standard of healthcare delivery and ultimately improving patient outcomes."}
{"id": "article-88698_1", "title": "Fludrocortisone -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of fludrocortisone. Evaluate\u00a0the potential adverse effects of fludrocortisone. Determine\u00a0the need for appropriate monitoring strategies for patients who are receiving fludrocortisone. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from\u00a0fludrocortisone\u00a0treatment. Access free multiple choice questions on this topic.", "contents": "Fludrocortisone -- Continuing Education Activity. Objectives: Identify the mechanism of action of fludrocortisone. Evaluate\u00a0the potential adverse effects of fludrocortisone. Determine\u00a0the need for appropriate monitoring strategies for patients who are receiving fludrocortisone. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from\u00a0fludrocortisone\u00a0treatment. Access free multiple choice questions on this topic."}
{"id": "article-88698_2", "title": "Fludrocortisone -- Indications", "content": "Fludrocortisone was granted a patent in 1953 and is on the World Health Organization's List of Essential Medicines.", "contents": "Fludrocortisone -- Indications. Fludrocortisone was granted a patent in 1953 and is on the World Health Organization's List of Essential Medicines."}
{"id": "article-88698_3", "title": "Fludrocortisone -- Indications -- FDA-Approved Indications", "content": "Fludrocortisone is essential in treating primary and secondary adrenocortical insufficiency due to its potent mineralocorticoid effect. [1] This drug may also be used to treat congenital adrenal hyperplasia (CAH). [2] CAH is a congenital enzymatic deficiency disorder with mineralocorticoid deficiency in up to 75% of cases.\u00a0The Endocrine Society guidelines endorse fludrocortisone\u00a0for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. [3]", "contents": "Fludrocortisone -- Indications -- FDA-Approved Indications. Fludrocortisone is essential in treating primary and secondary adrenocortical insufficiency due to its potent mineralocorticoid effect. [1] This drug may also be used to treat congenital adrenal hyperplasia (CAH). [2] CAH is a congenital enzymatic deficiency disorder with mineralocorticoid deficiency in up to 75% of cases.\u00a0The Endocrine Society guidelines endorse fludrocortisone\u00a0for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. [3]"}
{"id": "article-88698_4", "title": "Fludrocortisone -- Indications -- Off-Label Uses", "content": "According to ACC/AHA/HRS guidelines, fludrocortisone can be prescribed for syncope due to neurogenic orthostatic hypotension.\u00a0Fludrocortisone may be considered in cases of recurrent vasovagal syncope with an insufficient response to increased salt and water intake. [4] [5] The 2015 Heart Rhythm Society\u00a0guidelines endorses\u00a0fludrocortisone for\u00a0postural orthostatic tachycardia syndrome (POTS). [6] It has also been used in the management of septic shock in adults, demonstrating a 90-day all-cause mortality reduction among the group receiving hydrocortisone plus fludrocortisone than among those with a placebo. [7] [8] [9] [10] In a recent network meta-analysis of 17 randomized trials involving adult patients with septic shock, the combination of fludrocortisone plus hydrocortisone emerged as more effective in reducing all-cause mortality. [11]", "contents": "Fludrocortisone -- Indications -- Off-Label Uses. According to ACC/AHA/HRS guidelines, fludrocortisone can be prescribed for syncope due to neurogenic orthostatic hypotension.\u00a0Fludrocortisone may be considered in cases of recurrent vasovagal syncope with an insufficient response to increased salt and water intake. [4] [5] The 2015 Heart Rhythm Society\u00a0guidelines endorses\u00a0fludrocortisone for\u00a0postural orthostatic tachycardia syndrome (POTS). [6] It has also been used in the management of septic shock in adults, demonstrating a 90-day all-cause mortality reduction among the group receiving hydrocortisone plus fludrocortisone than among those with a placebo. [7] [8] [9] [10] In a recent network meta-analysis of 17 randomized trials involving adult patients with septic shock, the combination of fludrocortisone plus hydrocortisone emerged as more effective in reducing all-cause mortality. [11]"}
{"id": "article-88698_5", "title": "Fludrocortisone -- Mechanism of Action", "content": "Fludrocortisone acetate is an inactive pro-drug requiring hydrolyzation by esterases or pseudo-esterases in the liver and other body fluids. [12] Fludrocortisone is a synthetic adrenal steroid with high mineralocorticoid activity and is practically devoid of glucocorticoid effect. As an analog, its mechanism of action and the permissive effects on \u03b1-adrenoreceptors are similar to the endogenous mineralocorticoid. High lipid solubility allows fludrocortisone to penetrate the plasma membrane easily and bind with its cytoplasmic receptor.", "contents": "Fludrocortisone -- Mechanism of Action. Fludrocortisone acetate is an inactive pro-drug requiring hydrolyzation by esterases or pseudo-esterases in the liver and other body fluids. [12] Fludrocortisone is a synthetic adrenal steroid with high mineralocorticoid activity and is practically devoid of glucocorticoid effect. As an analog, its mechanism of action and the permissive effects on \u03b1-adrenoreceptors are similar to the endogenous mineralocorticoid. High lipid solubility allows fludrocortisone to penetrate the plasma membrane easily and bind with its cytoplasmic receptor."}
{"id": "article-88698_6", "title": "Fludrocortisone -- Mechanism of Action", "content": "Upon binding, the receptor complex translocates to the nucleus and initiates the transcription of responsive genes to exert its effects. The primary sites of fludrocortisone's effect are the distal convoluted tubules and collecting ducts, which enhance Na + and water retention and increase K + and H + excretion. This pharmacologic effect leads to a generalized ECF volume expansion not explicitly targeted to the intravascular space. Thus, it is postulated that its efficacy in orthostatic hypotension management is due to potentiating the pressor effects of various endogenous vasoconstrictors such as norepinephrine and angiotensin II. [13]", "contents": "Fludrocortisone -- Mechanism of Action. Upon binding, the receptor complex translocates to the nucleus and initiates the transcription of responsive genes to exert its effects. The primary sites of fludrocortisone's effect are the distal convoluted tubules and collecting ducts, which enhance Na + and water retention and increase K + and H + excretion. This pharmacologic effect leads to a generalized ECF volume expansion not explicitly targeted to the intravascular space. Thus, it is postulated that its efficacy in orthostatic hypotension management is due to potentiating the pressor effects of various endogenous vasoconstrictors such as norepinephrine and angiotensin II. [13]"}
{"id": "article-88698_7", "title": "Fludrocortisone -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Fludrocortisone is well absorbed with a Tmax of 0.5 to 2 hours. Distribution: The apparent volume of distribution for fludrocortisone is substantial, ranging from 80 to 85 L, with minimal observed penetration into the cerebrospinal fluid.", "contents": "Fludrocortisone -- Mechanism of Action -- Pharmacokinetics. Absorption: Fludrocortisone is well absorbed with a Tmax of 0.5 to 2 hours. Distribution: The apparent volume of distribution for fludrocortisone is substantial, ranging from 80 to 85 L, with minimal observed penetration into the cerebrospinal fluid."}
{"id": "article-88698_8", "title": "Fludrocortisone -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: As explained earlier, fludrocortisone acetate is an inactive pro-drug requiring hydrolyzation by esterases or pseudo-esterases in the liver. [12] The significant mineralocorticoid effects of fludrocortisone are due to the reduction in 11\u03b2-oxidation.", "contents": "Fludrocortisone -- Mechanism of Action -- Pharmacokinetics. Metabolism: As explained earlier, fludrocortisone acetate is an inactive pro-drug requiring hydrolyzation by esterases or pseudo-esterases in the liver. [12] The significant mineralocorticoid effects of fludrocortisone are due to the reduction in 11\u03b2-oxidation."}
{"id": "article-88698_9", "title": "Fludrocortisone -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: Approximately 80% of fludrocortisone is excreted in urine, while the remaining 20% is expected to be eliminated via feces or bile. Population pharmacokinetics estimate the plasma clearance of fludrocortisone to be around 40.8 L/h. Despite reported variations in plasma half-life, spanning from 1 to 3.5 hours, the provided prescribing information generally indicates an approximate half-life ranging from 18 to 36 hours for fludrocortisone. (Data adapted from PubChem)", "contents": "Fludrocortisone -- Mechanism of Action -- Pharmacokinetics. Elimination: Approximately 80% of fludrocortisone is excreted in urine, while the remaining 20% is expected to be eliminated via feces or bile. Population pharmacokinetics estimate the plasma clearance of fludrocortisone to be around 40.8 L/h. Despite reported variations in plasma half-life, spanning from 1 to 3.5 hours, the provided prescribing information generally indicates an approximate half-life ranging from 18 to 36 hours for fludrocortisone. (Data adapted from PubChem)"}
{"id": "article-88698_10", "title": "Fludrocortisone -- Administration -- Available Dosage Forms and Strengths", "content": "Fludrocortisone acetate is available in tablet form, with each tablet containing 0.1 mg of the medication. Fludrocortisone can be taken orally with or without a meal.", "contents": "Fludrocortisone -- Administration -- Available Dosage Forms and Strengths. Fludrocortisone acetate is available in tablet form, with each tablet containing 0.1 mg of the medication. Fludrocortisone can be taken orally with or without a meal."}
{"id": "article-88698_11", "title": "Fludrocortisone -- Administration -- Adult Dosage", "content": "Primary adrenal cortical insufficiency: The usual\u00a0dosage for primary adrenal cortical insufficiency is 0.1 mg daily, which can be increased to 0.2 mg daily. However, if hypertension develops, the dosage should be reduced to 0.05 mg per day. Dosing should be gradually tapered down to discontinue therapy. Congenital adrenal hyperplasia: The appropriate dose for salt-losing type congenital adrenal hyperplasia is 0.1 mg daily.", "contents": "Fludrocortisone -- Administration -- Adult Dosage. Primary adrenal cortical insufficiency: The usual\u00a0dosage for primary adrenal cortical insufficiency is 0.1 mg daily, which can be increased to 0.2 mg daily. However, if hypertension develops, the dosage should be reduced to 0.05 mg per day. Dosing should be gradually tapered down to discontinue therapy. Congenital adrenal hyperplasia: The appropriate dose for salt-losing type congenital adrenal hyperplasia is 0.1 mg daily."}
{"id": "article-88698_12", "title": "Fludrocortisone -- Administration -- Adult Dosage", "content": "Orthostatic hypotension: When used off-label for orthostatic hypotension, the\u00a0dosage is normally from 0.1 to 0.2 mg orally once daily. Dosing should start at 0.1 mg by mouth each day, then increase the dose by 0.1 mg per day each week until the appearance of trace pedal edema. The maximum\u00a0dosage is 1 mg daily, although doses over 0.5 mg are rarely more effective. Fludrocortisone should be administered with food or milk. Discontinuation of therapy requires gradual dose tapering.", "contents": "Fludrocortisone -- Administration -- Adult Dosage. Orthostatic hypotension: When used off-label for orthostatic hypotension, the\u00a0dosage is normally from 0.1 to 0.2 mg orally once daily. Dosing should start at 0.1 mg by mouth each day, then increase the dose by 0.1 mg per day each week until the appearance of trace pedal edema. The maximum\u00a0dosage is 1 mg daily, although doses over 0.5 mg are rarely more effective. Fludrocortisone should be administered with food or milk. Discontinuation of therapy requires gradual dose tapering."}
{"id": "article-88698_13", "title": "Fludrocortisone -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: There are no dosage adjustments for fludrocortisone provided in the\u00a0product labeling; use with caution. Renal impairment: No dosage adjustments for fludrocortisone are provided in the\u00a0product labeling; use with caution due to the potential for\u00a0volume\u00a0overload.", "contents": "Fludrocortisone -- Administration -- Specific Patient Populations. Hepatic impairment: There are no dosage adjustments for fludrocortisone provided in the\u00a0product labeling; use with caution. Renal impairment: No dosage adjustments for fludrocortisone are provided in the\u00a0product labeling; use with caution due to the potential for\u00a0volume\u00a0overload."}
{"id": "article-88698_14", "title": "Fludrocortisone -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: Fludrocortisone is a category C pregnancy drug. Fludrocortisone acetate should only be given to a pregnant woman if absolutely necessary. Additionally, infants born to mothers who received substantial doses of fludrocortisone acetate during pregnancy should be carefully observed for signs of hypoadrenalism. According to the Heart Rhythm Society (HRS) guidelines 2023, syncope is common in pregnancy due to altered venous return and cardiac output; vasovagal syncope is most commonly encountered. Conservative measures, such as increasing salt and water intake and avoiding triggers, are first-line therapies. Increased salt intake and fludrocortisone may be helpful in refractory cases after the first trimester. [14]", "contents": "Fludrocortisone -- Administration -- Specific Patient Populations. Pregnancy considerations: Fludrocortisone is a category C pregnancy drug. Fludrocortisone acetate should only be given to a pregnant woman if absolutely necessary. Additionally, infants born to mothers who received substantial doses of fludrocortisone acetate during pregnancy should be carefully observed for signs of hypoadrenalism. According to the Heart Rhythm Society (HRS) guidelines 2023, syncope is common in pregnancy due to altered venous return and cardiac output; vasovagal syncope is most commonly encountered. Conservative measures, such as increasing salt and water intake and avoiding triggers, are first-line therapies. Increased salt intake and fludrocortisone may be helpful in refractory cases after the first trimester. [14]"}
{"id": "article-88698_15", "title": "Fludrocortisone -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: Corticosteroids are present in the breast milk of lactating women receiving systemic therapy. Caution is advised when administering fludrocortisone acetate to nursing women.", "contents": "Fludrocortisone -- Administration -- Specific Patient Populations. Breastfeeding considerations: Corticosteroids are present in the breast milk of lactating women receiving systemic therapy. Caution is advised when administering fludrocortisone acetate to nursing women."}
{"id": "article-88698_16", "title": "Fludrocortisone -- Administration -- Specific Patient Populations", "content": "Pediatric patients: Fludrocortisone is\u00a0used off-label\u00a0for\u00a0cerebral salt wasting, characterized by inappropriate natriuresis and volume contraction in the presence of cerebral pathology. There have been reports of successful outcomes, underscoring its efficacy in managing this challenging condition. [15] A\u00a0retrospective study investigated the effectiveness of fludrocortisone in pediatric vasovagal syncope (VVS). Among 67 patients, those treated with fludrocortisone showed a significantly lower recurrence rate of syncopal events (39.3%) compared to the no-medication group (64.1%). Additionally, the fludrocortisone group exhibited a higher rate of negative change in the follow-up tilt-table test (57.1%) compared to the no-medication group (28.2%). These findings suggest that fludrocortisone may be more effective in pediatric VVS. [16]", "contents": "Fludrocortisone -- Administration -- Specific Patient Populations. Pediatric patients: Fludrocortisone is\u00a0used off-label\u00a0for\u00a0cerebral salt wasting, characterized by inappropriate natriuresis and volume contraction in the presence of cerebral pathology. There have been reports of successful outcomes, underscoring its efficacy in managing this challenging condition. [15] A\u00a0retrospective study investigated the effectiveness of fludrocortisone in pediatric vasovagal syncope (VVS). Among 67 patients, those treated with fludrocortisone showed a significantly lower recurrence rate of syncopal events (39.3%) compared to the no-medication group (64.1%). Additionally, the fludrocortisone group exhibited a higher rate of negative change in the follow-up tilt-table test (57.1%) compared to the no-medication group (28.2%). These findings suggest that fludrocortisone may be more effective in pediatric VVS. [16]"}
{"id": "article-88698_17", "title": "Fludrocortisone -- Administration -- Specific Patient Populations", "content": "Older patients: In older adults, fludrocortisone therapy may exacerbate conditions such as hypertension, edema, hypokalemia, congestive heart failure, cataracts, glaucoma, increased intraocular pressure, renal insufficiency, and osteoporosis. Caution and close monitoring are advised, and dose adjustments are made as needed.", "contents": "Fludrocortisone -- Administration -- Specific Patient Populations. Older patients: In older adults, fludrocortisone therapy may exacerbate conditions such as hypertension, edema, hypokalemia, congestive heart failure, cataracts, glaucoma, increased intraocular pressure, renal insufficiency, and osteoporosis. Caution and close monitoring are advised, and dose adjustments are made as needed."}
{"id": "article-88698_18", "title": "Fludrocortisone -- Adverse Effects", "content": "Most of the\u00a0adverse effects of fludrocortisone are related to mineralocorticoid activity. If this drug is used along with glucocorticoid or other related drugs, the adverse effect increases. Some of the more common or significant\u00a0adverse\u00a0effects\u00a0appear in the list below: Cardiovascular system:\u00a0Hypertension (dose-dependent; has been described as an adverse effect on children using fludrocortisone for CAH, which correlates with plasma renin activity), fluid retention, and edema (may cause swelling of lower limbs), congestive heart failure. [17] [18] Nervous System:\u00a0Headache, increased intracranial pressure, vertigo, change in behavior, convulsion Gastrointestinal: Stomach ulcer and perforation; the gastric protective barrier is impaired Endocrine: Menstrual abnormalities, cushingoid features, growth delay in a child, acute adrenal insufficiency in times of stress", "contents": "Fludrocortisone -- Adverse Effects. Most of the\u00a0adverse effects of fludrocortisone are related to mineralocorticoid activity. If this drug is used along with glucocorticoid or other related drugs, the adverse effect increases. Some of the more common or significant\u00a0adverse\u00a0effects\u00a0appear in the list below: Cardiovascular system:\u00a0Hypertension (dose-dependent; has been described as an adverse effect on children using fludrocortisone for CAH, which correlates with plasma renin activity), fluid retention, and edema (may cause swelling of lower limbs), congestive heart failure. [17] [18] Nervous System:\u00a0Headache, increased intracranial pressure, vertigo, change in behavior, convulsion Gastrointestinal: Stomach ulcer and perforation; the gastric protective barrier is impaired Endocrine: Menstrual abnormalities, cushingoid features, growth delay in a child, acute adrenal insufficiency in times of stress"}
{"id": "article-88698_19", "title": "Fludrocortisone -- Adverse Effects", "content": "Musculoskeletal: Muscle weakness, reduced muscle mass, increased risk of osteoporosis and pathological fracture, vertebral compression, necrosis of femoral head Dermatologic: Increased sweating, poor wound healing, hirsutism, thinning of the skin, severe allergic reaction Ophthalmic: Cataracts,\u00a0glaucoma Metabolic: Elevated blood and urine glucose, weight gain Electrolytes Disturbance:\u00a0Severe hypokalemia, metabolic alkalosis [19]", "contents": "Fludrocortisone -- Adverse Effects. Musculoskeletal: Muscle weakness, reduced muscle mass, increased risk of osteoporosis and pathological fracture, vertebral compression, necrosis of femoral head Dermatologic: Increased sweating, poor wound healing, hirsutism, thinning of the skin, severe allergic reaction Ophthalmic: Cataracts,\u00a0glaucoma Metabolic: Elevated blood and urine glucose, weight gain Electrolytes Disturbance:\u00a0Severe hypokalemia, metabolic alkalosis [19]"}
{"id": "article-88698_20", "title": "Fludrocortisone -- Adverse Effects -- Drug-Drug Interactions", "content": "Antacids: Administration of fludrocortisone with proton pump inhibitors and\u00a0antacids\u00a0has been shown to decrease its absorption. [12] Concurrent use of amphotericin B, diuretics, and digoxin with fludrocortisone may cause severe hypokalemia. [20] NSAIDS: Concurrent use of fludrocortisone with NSAIDs can\u00a0increase the risk of\u00a0peptic ulcer disease. [21] Warfarin: Fludrocortisone can alter the efficacy of\u00a0warfarin. Patients' PT/INR levels should be monitored. Oral hypoglycemic agents:\u00a0Fludrocortisone can cause hyperglycemia, so dosages of diabetes drugs (metformin, glipizide, glimepiride, pioglitazone, linagliptin, insulin) must be adjusted. Enzyme inducers: Administration of\u00a0phenobarbital, phenytoin, and rifampin\u00a0can lower blood fludrocortisone levels. Hormones: Taking estrogen or male testosterone analog with\u00a0fludrocortisone can increase the risk of swelling.", "contents": "Fludrocortisone -- Adverse Effects -- Drug-Drug Interactions. Antacids: Administration of fludrocortisone with proton pump inhibitors and\u00a0antacids\u00a0has been shown to decrease its absorption. [12] Concurrent use of amphotericin B, diuretics, and digoxin with fludrocortisone may cause severe hypokalemia. [20] NSAIDS: Concurrent use of fludrocortisone with NSAIDs can\u00a0increase the risk of\u00a0peptic ulcer disease. [21] Warfarin: Fludrocortisone can alter the efficacy of\u00a0warfarin. Patients' PT/INR levels should be monitored. Oral hypoglycemic agents:\u00a0Fludrocortisone can cause hyperglycemia, so dosages of diabetes drugs (metformin, glipizide, glimepiride, pioglitazone, linagliptin, insulin) must be adjusted. Enzyme inducers: Administration of\u00a0phenobarbital, phenytoin, and rifampin\u00a0can lower blood fludrocortisone levels. Hormones: Taking estrogen or male testosterone analog with\u00a0fludrocortisone can increase the risk of swelling."}
{"id": "article-88698_21", "title": "Fludrocortisone -- Adverse Effects", "content": "Vaccines: Fludrocortisone's immunosuppressive properties may compromise vaccine efficacy. Therefore, it is recommended that vaccines be avoided during fludrocortisone use.", "contents": "Fludrocortisone -- Adverse Effects. Vaccines: Fludrocortisone's immunosuppressive properties may compromise vaccine efficacy. Therefore, it is recommended that vaccines be avoided during fludrocortisone use."}
{"id": "article-88698_22", "title": "Fludrocortisone -- Contraindications", "content": "Fludrocortisone is contraindicated in several conditions. Clinicians should conduct a careful history and examination before prescribing this drug. If there is any contraindication to this drug, alternative options should be considered. Contraindications include: Known allergy to fludrocortisone or its excipients [22] Systemic fungal infection", "contents": "Fludrocortisone -- Contraindications. Fludrocortisone is contraindicated in several conditions. Clinicians should conduct a careful history and examination before prescribing this drug. If there is any contraindication to this drug, alternative options should be considered. Contraindications include: Known allergy to fludrocortisone or its excipients [22] Systemic fungal infection"}
{"id": "article-88698_23", "title": "Fludrocortisone -- Contraindications -- Warning and Precautions", "content": "Clinicians should prescribe fludrocortisone with caution in patients with hypertension or hypoalbuminemia. Fludrocortisone acetate is reserved for active tuberculosis cases requiring corticosteroid use in conjunction with antituberculous treatment. In latent tuberculosis or tuberculin reactivity, cautious monitoring is crucial, and chemoprophylaxis is recommended during prolonged corticosteroid therapy.", "contents": "Fludrocortisone -- Contraindications -- Warning and Precautions. Clinicians should prescribe fludrocortisone with caution in patients with hypertension or hypoalbuminemia. Fludrocortisone acetate is reserved for active tuberculosis cases requiring corticosteroid use in conjunction with antituberculous treatment. In latent tuberculosis or tuberculin reactivity, cautious monitoring is crucial, and chemoprophylaxis is recommended during prolonged corticosteroid therapy."}
{"id": "article-88698_24", "title": "Fludrocortisone -- Monitoring", "content": "Since this drug can cause a life-threatening hypersensitivity reaction, the patient must be monitored for the development of any allergic sign symptoms such as rash, breathing problem, swelling of the face, or fever. Blood pressure should be recorded regularly while using this corticosteroid as it has been associated with iatrogenic hypertension. Serial plasma renin activity should also be checked. If there is weakness or muscle cramps,\u00a0serum electrolytes should be checked to identify and treat hypokalemia. [20] Monitoring serum blood glucose levels is essential to manage hyperglycemia during fludrocortisone therapy, especially in\u00a0patients with diabetes. If the drug is being\u00a0prescribed for a child for a longer duration, the growth and development of the child should be tracked to see if there is any delay in growth.", "contents": "Fludrocortisone -- Monitoring. Since this drug can cause a life-threatening hypersensitivity reaction, the patient must be monitored for the development of any allergic sign symptoms such as rash, breathing problem, swelling of the face, or fever. Blood pressure should be recorded regularly while using this corticosteroid as it has been associated with iatrogenic hypertension. Serial plasma renin activity should also be checked. If there is weakness or muscle cramps,\u00a0serum electrolytes should be checked to identify and treat hypokalemia. [20] Monitoring serum blood glucose levels is essential to manage hyperglycemia during fludrocortisone therapy, especially in\u00a0patients with diabetes. If the drug is being\u00a0prescribed for a child for a longer duration, the growth and development of the child should be tracked to see if there is any delay in growth."}
{"id": "article-88698_25", "title": "Fludrocortisone -- Toxicity -- Signs and Symptoms of Overdose", "content": "The toxicity of any drug depends on\u00a0its pharmacological activity. Since fludrocortisone works\u00a0on mineralocorticoid receptors, toxicity will present as excess mineralocorticoid activities such as severe hypertension, not pitting edema, congestive heart failure, severe hypokalemia, metabolic alkalosis, and rapid weight gain. [23] One case report describes a 41-year-old woman diagnosed with adrenal insufficiency who developed Takotsubo cardiomyopathy following the initiation of hormone replacement therapy with hydrocortisone and fludrocortisone (0.3 mg/day). Notably, her cardiac function significantly improved after a substantial reduction in fludrocortisone dosage to 0.05 mg/day. [23]", "contents": "Fludrocortisone -- Toxicity -- Signs and Symptoms of Overdose. The toxicity of any drug depends on\u00a0its pharmacological activity. Since fludrocortisone works\u00a0on mineralocorticoid receptors, toxicity will present as excess mineralocorticoid activities such as severe hypertension, not pitting edema, congestive heart failure, severe hypokalemia, metabolic alkalosis, and rapid weight gain. [23] One case report describes a 41-year-old woman diagnosed with adrenal insufficiency who developed Takotsubo cardiomyopathy following the initiation of hormone replacement therapy with hydrocortisone and fludrocortisone (0.3 mg/day). Notably, her cardiac function significantly improved after a substantial reduction in fludrocortisone dosage to 0.05 mg/day. [23]"}
{"id": "article-88698_26", "title": "Fludrocortisone -- Toxicity -- Management of Overdose", "content": "There is no antidote for fludrocortisone toxicity, making conservative management the mainstay of treatment. Reduction of dose, strict blood pressure control, and potassium supplementation may be given.", "contents": "Fludrocortisone -- Toxicity -- Management of Overdose. There is no antidote for fludrocortisone toxicity, making conservative management the mainstay of treatment. Reduction of dose, strict blood pressure control, and potassium supplementation may be given."}
{"id": "article-88698_27", "title": "Fludrocortisone -- Enhancing Healthcare Team Outcomes", "content": "Fludrocortisone is used worldwide and prescribed by clinicians, osteopathic clinicians, physician assistants, and nurse practitioners.\u00a0Since fludrocortisone can interact with many other medications and may cause serious adverse effects or toxicity,\u00a0interprofessional healthcare team members must be knowledgeable of these consequences.\u00a0All team members, whether involved in prescribing, dispensing, administering, or monitoring fludrocortisone,\u00a0must be well-educated about the pharmacology of this drug. A proper history and physical examination must be considered before initiating fludrocortisone. The patient\u00a0should\u00a0be educated about the adverse effects, potential toxicity,\u00a0and appropriate dosing of this drug so they can use\u00a0the medication properly. Patients should inform their clinician of adverse reactions or symptoms for prompt evaluation and management. For congenital adrenal hyperplasia, consult an endocrinologist and a pediatrician for the best care.\u00a0Referral to a cardiologist may be required when considering fludrocortisone for\u00a0postural orthostatic tachycardia syndrome.", "contents": "Fludrocortisone -- Enhancing Healthcare Team Outcomes. Fludrocortisone is used worldwide and prescribed by clinicians, osteopathic clinicians, physician assistants, and nurse practitioners.\u00a0Since fludrocortisone can interact with many other medications and may cause serious adverse effects or toxicity,\u00a0interprofessional healthcare team members must be knowledgeable of these consequences.\u00a0All team members, whether involved in prescribing, dispensing, administering, or monitoring fludrocortisone,\u00a0must be well-educated about the pharmacology of this drug. A proper history and physical examination must be considered before initiating fludrocortisone. The patient\u00a0should\u00a0be educated about the adverse effects, potential toxicity,\u00a0and appropriate dosing of this drug so they can use\u00a0the medication properly. Patients should inform their clinician of adverse reactions or symptoms for prompt evaluation and management. For congenital adrenal hyperplasia, consult an endocrinologist and a pediatrician for the best care.\u00a0Referral to a cardiologist may be required when considering fludrocortisone for\u00a0postural orthostatic tachycardia syndrome."}
{"id": "article-88698_28", "title": "Fludrocortisone -- Enhancing Healthcare Team Outcomes", "content": "Interprofessional team\u00a0discussion\u00a0that includes all clinicians (including specialists such as endocrinologists), nursing staff, and pharmacists\u00a0is crucial for every patient. The interprofessional team must monitor the patient regularly and be ready for a prompt response if there are any signs or symptoms of adverse events. Family members should also be educated about proper dosing, adverse effects, and warning signs. This team approach will drive improved patient outcomes and mitigate potential adverse events. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), nurses, specialists, and pharmacists are necessary to\u00a0optimize patient outcomes with\u00a0fludrocortisone.", "contents": "Fludrocortisone -- Enhancing Healthcare Team Outcomes. Interprofessional team\u00a0discussion\u00a0that includes all clinicians (including specialists such as endocrinologists), nursing staff, and pharmacists\u00a0is crucial for every patient. The interprofessional team must monitor the patient regularly and be ready for a prompt response if there are any signs or symptoms of adverse events. Family members should also be educated about proper dosing, adverse effects, and warning signs. This team approach will drive improved patient outcomes and mitigate potential adverse events. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), nurses, specialists, and pharmacists are necessary to\u00a0optimize patient outcomes with\u00a0fludrocortisone."}
{"id": "article-88698_29", "title": "Fludrocortisone -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Fludrocortisone -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}